- $14.48m
- $19.60m
- $52.68m
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:54 PM
Iridex Corp Reports Results For The Quarter Ended June 30: Earnings Summary
Iridex Q2 revenue falls as retina sales decline
Iridex Corp Expected To Post A Loss Of 1 Cent A Share: Earnings Preview
Iridex Q1 revenue falls 1%, loss narrows
Iridex Q4 revenue rises on higher retina system sales
Laser eye device maker Iridex's Q3 net loss narrows
Brief: Iridex Corporation Receives Formal Notification Of Nasdaq Listing Compliance
Brief: Iridex Announces First Patient Enrolled In An Independent Landmark Investigator
Brief: Iridex Q1 Revenue USD 11.9 Million
Brief: Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2024
Brief: Iridex Comments On Changing Glaucoma Reimbursement Landscape
Brief: Iridex Appoints Patrick Mercer As Chief Executive Officer
Iridex Corp Reports Results For The Quarter Ended In June: Earnings Summary
Iridex Corp Expected To Post A Loss Of 12 Cents A Share: Earnings Preview
Iridex Corp Reports Results For The Quarter Ended In March: Earnings Summary
Iridex Corp Expected To Post A Loss Of 12 Cents A Share: Earnings Preview
Iridex Corp Reports Results For The Quarter Ended In December: Earnings Summary
Iridex Corp Expected To Post A Loss Of 5 Cents A Share: Earnings Preview